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Original article
Hypertension is an important risk factor for cardiovascular 
disease, the leading cause of mortality all over the globe.1 
Hypertension is a worldwide problem2 and its prevalence is 
increasing in China.3 According to the data from the 2007–
2008 China National Diabetes and Metabolic Disorders 
Study, 26.6% of Chinese adults have hypertension,3 causing 
considerable health and economic burden.4,5
The etiology of high blood pressure involves the interplay 
among many factors. Risk factors include body mass index 
(BMI), tobacco use, salt and alcohol intake, and physical activity.6 
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BACKGROUND
The objective of this study was to investigate the genetic association of 
4 candidate variants with blood pressure and test the modifying effects 
of environmental factors including age, sex, and body mass index (BMI).
METHODS
We used a linear mixed-effects model to test for variant main effects 
and variant interactions with age, sex, and BMI on systolic (SBP) and 
diastolic (DBP) blood pressure in 7,319 Chinese adults from the China 
Health and Nutrition Survey (CHNS). We attempted to replicate 
our significant interaction findings in 1,996 Chinese men from the 
Fangchenggang Area Male Health and Examination Survey (FAMHES).
RESULTS
Two variants (rs11105378 near ATP2B1 and rs1458038 near FGF5) 
were significantly associated (P  <  0.00625  =  0.05/8) with both 
SBP and DBP in CHNS. Variant rs1378942 near CSK was nominally 
associated with SBP (P  =  0.01). The signal at rs1458038 exhib-
ited a genotype-by-BMI interaction affecting blood pressure 
(Pinteraction  =  0.0018 for SBP; Pinteraction  =  0.049 for DBP), with the 
strongest variant effects in those with the highest BMI. In FAMHES, 
rs1458038 also showed stronger effects on SBP and DBP among 
men with the highest BMI.
CONCLUSIONS
Our findings suggest high BMI increases the effect of the blood pres-
sure-increasing allele at rs1458038 near FGF5, further highlighting the 
importance of obesity prevention in reducing hypertension risk.
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An estimated 30–60% of blood pressure variation is explained 
by genetic factors.7 Many genetic variants have been identified 
by genome-wide association studies conducted in multiple pop-
ulations. Blood pressure is a complex phenotype, and the effects 
of some variants may be stronger in individuals exposed to spe-
cific environmental factors. However, relatively few studies have 
investigated the possible interaction between genetic variants 
and environmental factors in affecting blood pressure.
Several loci first identified in subjects of European descent, 
including ATP2B1 on chromosome 12q21.33, FGF5 on 
4q21.21, CYP17A1 on 10q24.32, and CSK on 15q24.1 have 
been validated in East Asians.8,9 In this study, we genotyped 
index variants from these 4 candidate loci and examined 
whether the associations with systolic (SBP) and diastolic 
(DBP) blood pressure could be replicated in 7,319 adults 
(18 years and older) from 9 provinces in the China Health 
and Nutrition Survey (CHNS). We further tested whether 
the associations were influenced by environmental factors 
including age, sex, and BMI. Finally, we attempted to repli-
cate specific findings in 1,996 men from the Fangchenggang 
Area Male Health and Examination Survey (FAMHES).
METHODS
Study design: CHNS. CHNS is a nationwide longitudinal 
survey designed to examine a series of economic, sociological, 
demographic, and health questions in the Chinese population. 
The design of CHNS has been described in detail elsewhere.10 
This study was conducted in 9 provinces in China that vary sig-
nificantly in terms of socioeconomic, health-related, and nutri-
tional status. The sample from each province was drawn using 
a multistage, random cluster procedure, designed to select a 
stratified probability sample in each province, with selection 
of larger cities and smaller suburban and rural villages, from 
which households were randomly selected. Approximately 
19,000 individuals from ~4,400 households participated in 
the overall survey. The first round of data was collected in 
1989, followed by 8 additional waves of data collected in 1991, 
1993, 1997, 2000, 2004, 2006, 2009, and 2011. The study was 
approved by the ethics committee at the National Institute of 
Nutrition and Food Safety at the China Center for Disease 
Control and Prevention and the Institutional Review Board at 
the University of North Carolina at Chapel Hill. Written con-
sent was obtained from subjects surveyed in 2009.
Data collection and phenotypes. For this study, we 
used dietary, clinical, and anthropometric data collected 
from participants who were age 18  years or older and not 
pregnant at the time of the 2009 survey. Blood pressure 
was measured 3 consecutive times on the same day, with 
10 minutes of seated rest before the first measurement and 
3–5 minutes intervals between each measurement. SBP and 
DBP were determined by the first and fifth phase Korotkoff 
sounds,11 respectively. The average of the 3 measurements 
was used for analyses. For participants who take antihyper-
tensive medications, 10 and 5 mm Hg was added to the aver-
age SBP and DBP, respectively.12,13 The smoking responses 
were dichotomized to define current smoking status. Total 
salt intake (grams) was estimated based on a combination of 
3 consecutive 24-hour food recalls at the individual level and 
a food inventory at the household level.14
Genotyping. Fasting venous blood was collected and 
stored at −80  °C, and DNA was extracted from buffy coat 
using the FlexiGene DNA kit (Qiagen, Valencia, CA), 
according to the manufacturer’s instructions. Four candi-
date variants for blood pressure,9 including rs11105378 at 
ATP2B1, rs1458038 at FGF5, rs1004467 at CYP17A1, and 
rs1378942 at CSK-CYP1A1, were genotyped using TaqMan 
chemistry (Applied Biosystems). TaqMan genotyping assays 
with probes labeled with the fluorophores FAM and VIC 
were purchased from Applied Biosystems. The Universal 
PCR Master Mix from Applied Biosystems was used in a 5 µl 
total reaction volume with 10 ng DNA per reaction. Allelic 
discrimination was measured automatically on ABI Prism 
7900HT (Applied Biosystems) with Sequence Detection 
Systems. Among 8,221 individuals genotyped, the success 
rate for each variant was >98%. Genotype distributions were 
consistent with Hardy–Weinberg equilibrium expectations 
(P > 0.05). The concordance rate between 301 duplicate pairs 
across all variants was >99.9%.
Statistical analyses. A total of 7,319 nonpregnant adults, 
age 18  years or older at the time of blood pressure meas-
urement, with complete phenotype, covariate, and genotype 
data were included in tests of association between variants 
and SBP or DBP. The distributions of SBP and DBP, after 
accounting for age, sex, and BMI, showed no significant 
deviation from normality; untransformed traits were ana-
lyzed. Linear mixed-effects models,15 with a random effect 
for household to account for the correlation between blood 
pressure measurements from members in the same family, 
were used to test the variant additive genetic main effects. 
The base models included adjustment for covariates signifi-
cantly (P < 0.05) associated with SBP or DBP; namely, age, 
sex, province, and BMI. Additional models also included 
covariate adjustment for current smoking status and total 
salt intake. Each variant that showed evidence for a main 
effect association (P < 0.05) with either SBP or DBP was fur-
ther analyzed for variant-by-environment interactions with 
age, sex, and BMI by including an interaction term to the 
above base linear mixed-effects model. Stratified analyses 
were performed for variants demonstrating evidence of a 
significant interaction (Pinteraction < 0.05) by categorizing par-
ticipants according to quartiles of the environmental factor 
and testing main effects of the variants within each quartile.
Follow-up sample: FAMHES. We followed up our gen-
otype-by-BMI interaction finding at rs1458038 near FGF5 
in 1,996 men from the FAMHES study using linear regres-
sion models with covariate adjustment for age and the main 
effects for genotype and BMI. As with CHNS, we also per-
formed stratified analyses for the main effects of rs1458038 
on SBP and DBP in strata defined by BMI quartiles of the 
FAMHES participants. The FAMHES project was conducted 
in Fangchenggang city, Guangxi, southern China in 2009.16 
The men were 20–69 years old (average age 37.5 ± 11.1 years) 
and of self-reported southern Chinese Han ethnicity.17 About 
50.8% of men were reported smokers and the average BMI 
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was 23.1 ± 3.4 kg/m2. Written informed consent to participate 
in the study was provided by all participating men; the study 
was approved by the Wake Forest University Institutional 
Review Board. All samples were genotyped on the Illumina 
HumanOmni1-Quad BeadChip. A single measure of blood 
pressure on each FAMHES participant was taken by apply-
ing a mercury sphygmomanometer to the right arm of the 
participants after they were seated in a comfortable sitting 
position for an at least 5-minute rest period.
RESULTS
Overall, 7,319 CHNS subjects (3,987 females and 3,332 
males) with complete phenotype (average SBP and DBP), 
essential covariates (age, sex, BMI, and province), and gen-
otype data were included in the analyses (Table 1). Higher 
age, male sex, larger BMI, and current smoking were each 
associated with higher SBP and DBP (data not shown, 
P  <  0.05). Higher salt intake was associated with higher 
DBP. Blood pressure levels were higher in residents from 
Northern provinces than in residents from Southern prov-
inces (Supplementary Table 1), which is consistent with the 
observed north-south gradient in the prevalence of hyper-
tension in China.18 When all covariates were included in a 
single model, current smoking status and total salt intake 
no longer showed evidence for association with SBP or DBP. 
Our base model, model 1, included covariates for age, sex, 
BMI, and province while our secondary model, model 2, had 
additional covariates for current smoking status and total 
salt intake.
Four candidate variants that were reported to be associ-
ated with SBP and/or DBP in prior studies7–9,19,20 were tested 
for association in CHNS. For the base model, 2 variants 
(rs11105378 near ATP2B1 and rs1458038 near FGF5) were 
significantly associated (P  <  0.00625  =  0.05/8) with both 
SBP and DBP (Table  2). Variant rs1378942 near CSK was 
nominally (P  <  0.05) associated with SBP (P  =  7.0 × 10−3). 
The direction and effect sizes for all 8 association tests were 
consistent with the previous reports. Additional covariate 
adjustment for current smoking status and total salt intake 
resulted in very similar findings compared to the base model 
(Table 2).
The 3 variants associated with SBP and 2 variants asso-
ciated with DBP were tested for interaction with each of 3 
environmental factors (age, sex, and BMI) that significantly 
affected blood pressure when controlling for all other covar-
iates. Among the 15 tests performed, 4 showed nominally 
significant results (Pinteraction < 0.05). The observed interac-
tion between rs1458038 and BMI on SBP was significant 
(Pinteraction  =  0.0018) after Bonferroni correction for multi-
ple tests (Pinteraction < 0.0033, 0.05/15 tests). The interaction 
between rs1458038 and BMI was also nominally associated 
(Pinteraction  =  0.049) with DBP. The 2 remaining nominally 
significant interactions were between rs1378942 and sex on 
SBP (Pinteraction = 0.045) and between rs11105378 and age on 
DBP (Pinteraction = 0.026).
Further analyses were conducted in CHNS to interrogate 
the interactions between rs1458038 and BMI on SBP and 
DBP. We stratified the samples according to BMI quartiles 
and performed main-effects regression analyses of rs1458038 
on SBP and DBP, adjusting for the base model covariates. 
The T allele of rs1458038 was significantly associated with 
higher SBP in the highest quartile of BMI, but the associa-
tion was not significant in lower quartiles (Table  3). The 
magnitude of the effect size estimates increased with BMI. 
A similar pattern of stronger effects of this variant in subjects 
with the highest BMI was observed for DBP (Table 3). The 
interaction between rs1458038 and BMI was only nominally 
associated with DBP (females: Pinteraction  =  0.0076; males: 
Pinteraction = 0.99) and SBP (females: Pinteraction = 0.0022; males: 
Pinteraction  =  0.16) in CHNS females (Supplementary Tables 
2 and 3), though the differences in effects were not statis-
tically significant (3-way interaction between rs1458038, 
BMI and sex including all pairwise 2-way interactions in 
the model) for either DBP (P3-way-interaction  =  0.12) or SBP 
(P3-way-interaction = 0.33).
In FAMHES, there was a trend (P ≤ 0.10) with consistent 
direction of effects to CHNS, for main effects of rs1458038 
on both DBP (P = 0.058) and SBP (P = 0.10) (Supplementary 
Table  4). The interaction effects between rs1458038 and 
BMI affecting SBP and DBP were in the same direction as 
CHNS but did not reach statistical significance in FAMHES 
(Pinteraction = 0.36 for DBP; Pinteraction = 0.62 for SBP). Consistent 
with the sex-combined results from CHNS, the estimates of 
Table 1. Characteristics of the China Health and Nutrition Survey participants analyzed
Characteristics
Female (n = 3,987) Male (n = 3,332) Total (n = 7,319)
Mean ± SD Median (range) Mean ± SD Median (range) Mean ± SD Median (range)
SBP (mm Hg) 124.3 ± 20.8 120.0 (76.7–266.7) 126.8 ± 18.2 122.0 (80.0–229.3) 125.4 ± 19.7 121.0 (76.7–266.7)
DBP (mm Hg) 79.4 ± 11.6 80.0 (44.0–152.0) 82.5 ± 11.3 80.7 (50.0–136.0) 80.8 ± 11.6 80.0 (44.0–152.0)
Age (years) 50.9 ± 15.0 51.1 (18.0–98.9) 50.7 ± 15.1 51.0 (18.0–92.3) 50.8 ± 15.0 51.0 (18.0–98.9)
BMI (kg/m2) 23.4 ± 3.5 23.0 (13.4–38.8) 23.4 ± 3.4 23.2 (13.4–37.2) 23.4 ± 3.5 23.1 (13.4–38.8)
Current smoker (%) 3.70% – 55.00% – 27.04% –
Total salt intake (grams) 4.5 ± 2.6 3.9 (0.1–22.2) 4.9 ± 2.7 4.3 (0.2–21.3) 4.7 ± 2.6 4.1 (0.1–22.2)
Values are means ± SD, medians (range), or %. The average of the 3 measurements of SBP or DBP was used for analysis. Total salt intake 
was based on a combination of 3 consecutive 24-hour food recalls at the individual level and a food inventory at the household level. The sample 
size is 7,315 with data on current smoking status and 7,063 with data on total salt intake.
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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the main effects of rs1458038 on SBP and DBP were strong-
est in men grouped in the highest quartile of BMI (Table 4).
DISCUSSION
In this study, we tested the association of 4 candidate vari-
ants with SBP and DBP in 7,319 Chinese individuals, from 
9 provinces, participating in CHNS and followed up our top 
findings in 1,996 Chinese men from the province of Guangxi 
participating in FAMHES.  rs1458038, 23 kb upstream of 
FGF5 on chromosome 4, and rs11105378, 41 kb upstream 
of ATP2B1 on chromosome 12, were significantly associ-
ated with both SBP and DBP (P < 0.00625) in CHNS while 
rs1378942, an intronic variant in CSK, was nominally associ-
ated with SBP (P = 7.0 × 10−3). We also detected a significant 
interaction between rs1458038 and BMI affecting SBP and a 
nominally significant interaction between this same variant 
and BMI affecting DBP in CHNS. Specifically, we showed 
that the effect of the rs1458038 risk genotype is stronger in 
subjects in the heaviest quartile of the BMI distribution.
rs1458038, and nearby variant rs16998073, were identi-
fied to be associated with DBP and SBP in Europeans19,20 
and in East Asians.8,9,21,22 We found no published evidence 
supporting rs1458038 to be an important regulatory variant 
(RegulomeDB (http://www.regulomedb.org) score: “mini-
mal binding evidence”; no evidence for being an eQTL in 
MuTHER (http://www.muther.ac.uk), GTEx (http://www.
gtexportal.org), or blood eQTL(http://genenetwork.nl/blod-
deqtlbrowser). rs11105378 was identified by the CHARGE 
and Global BPgen Consortia,7 and confirmed in Japanese.9 
Several other variants that are in high linkage disequilib-
rium with rs11105378 (r2 > 0.8 in CEU) were also identi-
fied in different ethnicities.7,8,19,23 rs11105378 was reported 
to be associated with expression of neighboring WDR51B 
(P  =  7.1 × 10−15) in blood (blood eQTL). Differences in 
ATP2B1 mRNA expression levels in umbilical artery 
Table 3. Mean levels of SBP and DBP by rs1458038 genotype and BMI quartile in CHNS
All participants CC CT TT N β (SE) P
SBP
 Q1 118.9 ± 18.6 118.7 ± 18.3 118.7 ± 18.2 120.1 ± 20.0 1,818 0.21 (0.54) 0.69
 Q2 122.8 ± 18.2 121.7 ± 17.4 123.0 ± 18.1 124.7 ± 20.2 1,818 0.88 (0.55) 0.11
 Q3 127.1 ± 18.7 126.2 ± 18.6 127.2 ± 18.1 128.6 ± 20.4 1,818 1.05 (0.55) 0.057
 Q4 132.8 ± 20.4 130.8 ± 19.2 133.4 ± 20.7 135.1 ± 21.6 1,818 2.93 (0.61) 1.9E-06
DBP
 Q1 76.4 ± 10.9 76.0 ± 10.6 76.4 ± 10.8 77.1 ± 11.6 1,818 0.33 (0.34) 0.34
 Q2 78.9 ± 10.8 78.7 ± 10.8 79.1 ± 10.6 78.9 ± 11.4 1,818 0.12 (0.34) 0.72
 Q3 82.2 ± 10.8 81.4 ± 11.0 82.5 ± 10.4 83.0 ± 11.3 1,818 0.80 (0.34) 0.021
 Q4 85.7 ± 11.7 85.1 ± 11.7 85.6 ± 11.9 87.4 ± 11.2 1,818 1.23 (0.38) 1.0E-03
Q1–Q4: the lowest BMI quartile to the highest BMI quartile. Q1: BMI < 20.93; Q2: 20.93 ≤ BMI < 23.11; Q3: 23.11 ≤ BMI < 25.65; Q4: BMI ≥ 
25.65. Values for SBP and DBP are mean ± SE.
Abbreviations: BMI, body mass index; CHNS, China Health and Nutrition Survey; DBP, diastolic blood pressure; SBP, systolic blood pressure; 
SE, standard error.
Table 2. Main effect association of variants with SBP and DBP in CHNS
Variant Chr Nearby Gene EA EAF Trait
Model 1 Model 2
Sample β SE P Sample β SE P
rs1458038 4 FGF5 T 0.42 SBP 7,272 1.29 0.28 2.8E-06 7,013 1.28 0.28 5.9E-06
DBP 0.70 0.17 5.2E-05 0.68 0.18 1.1E-04
rs1004467 10 CYP17A1 A 0.65 SBP 7,308 0.37 0.29 0.20 7,048 0.44 0.29 0.13
DBP 0.11 0.18 0.54 0.13 0.18 0.49
rs11105378 12 ATP2B1 C 0.66 SBP 7,187 1.22 0.29 3.3E-05 6,929 1.29 0.30 1.8E-05
DBP 0.73 0.18 6.9E-05 0.80 0.19 1.8E-05
rs1378942 15 CSK C 0.84 SBP 7,276 1.02 0.38 7.0E-03 7,018 0.97 0.39 0.012
DBP 0.35 0.24 0.14 0.36 0.24 0.14
β coefficients represent the estimated change in the level of blood pressure associated with each additional copy of the effect allele, designated 
as the blood pressure raising allele. Covariates for model 1 were age, gender, province, and BMI. Covariates for model 2 were age, gender, 
province, BMI, current smoking status, and total salt intake.
Abbreviations: BMI, body mass index; CHNS, China Health and Nutrition Survey; DBP, diastolic blood pressure; EA, effect allele; EAF, effect 
allele frequency; SBP, systolic blood pressure; SE, standard error.
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smooth muscle cells have also been observed among differ-
ent rs11105378 genotypes.9 rs1378942, an intronic variant 
2,306 bp from a splice site in CSK, was significantly associ-
ated with SBP and DBP in Europeans19; however, only nomi-
nal association was observed in East Asians8 and Japanese.9 
In our study, we only replicate (P < 0.05) its association with 
SBP, although the effect size estimates for both SBP and DBP 
were similar in both direction and size to the previous study 
in Japanese. There is some evidence for rs1378942 being an 
important regulatory variant (RegulomeDB score: “likely to 
affect binding and linked to gene expression of gene target”). 
rs1378942 has been reported to be associated with gene 
expression of a number of nearby genes, including CSK (in 
blood (P = 1.3 × 10−129) (in blood eQTL)) and ULK3 (in adi-
pose tissue (P  =  6.3 × 10−8), lymphocytes (1.0 × 10−20), skin 
(3.1 × 10−8) (in MuTHER) and blood (P  =  5.7 × 10−33) (in 
blood eQTL)). We failed to replicate blood pressure associa-
tions with rs1004467, an intronic variant 35 bp from a splice-
site in CYP17A1, in CHNS. Here too, our directions of effect 
were consistent with the previous Japanese study. However, 
the size of the effects for DBP and SBP were about half of 
those reported previously for this variant.
An interesting finding of this study is the evidence for 
interaction between rs1458038 and BMI in affecting both 
SBP and DBP in CHNS. BMI is a strong risk factor that 
affects blood pressure; the prevalence of hypertension and 
mean levels of SBP and DBP increase as BMI increases.24,25 
While variants 5′ of FGF5 at 4q21 are associated with blood 
pressure in the Chinese population,21,22 the interaction 
between these 2 risk factors on affecting blood pressure has 
not been previously reported. The strongest evidence for 
association between rs1458038 and blood pressure measures 
in CHNS were observed in participants in the highest quar-
tile of BMI. In FAMHES, the strongest effects of rs14358038 
for both blood pressure traits were also observed in the high-
est quartile of BMI.
When assessing the overall impact of the FAMHES 
results, some differences between CHNS and FAMHES 
are worth noting. FAMHES includes only males from the 
province of Guangxi, while CHNS includes both males and 
females from 9 provinces, including Guangxi. The sample 
size of FAMHES (n  =  1,996) is considerably smaller than 
that of CHNS (n = 7,319). FAMHES men were also younger, 
on average, than CHNS individuals. Both the average SBP 
and DBP measures were lower in FAMHES men compared 
to CHNS men; however, these results are consistent with the 
younger ages in FAMHES and the lower blood pressure val-
ues observed in CHNS men from Guangxi (Supplementary 
Table 1). SBP and DBP were measured only once in FAMHES 
compared to 3 measurements (we applied the average) in 
CHNS. Finally, no hypertensive medication history was 
available in FAMHES. In CHNS, 399 subjects were known to 
be on hypertensive medication and an offset was applied to 
the SBP and DPB measures in CHNS to account for medica-
tion use. Given these sampling differences between FAMHES 
and CHNS participants, it is possible that the interactions 
between BMI and rs14358038 affecting blood pressure may 
not be the same in the 2 cohorts. Interestingly, though the 
results were not significantly different, the observed inter-
actions between rs1458038 and BMI on the blood pressure 
measures were stronger in women than in men in CHNS.
Four genes including ANTXR2, PRDM8, FGF5, and 
C4orf22 are located near rs1458038. ANTXR2 encodes 
anthrax toxin receptor 2, a protein involved in angiogen-
esis.26 A recent functional study,27 using in vivo small inter-
fering RNA silencing in mice, suggested ANTXR2 is the 
most likely causative gene in the 4q21 region that regulates 
individual differences in blood pressure in humans. The 
study proposed that the lower Antxr2 expression can lead 
to a decrease in the proliferation of endothelial cells, prevent 
the formation of capillary network, and result in microvas-
cular rarefaction and increase of BP. Many studies observed 
a developing microvascular rarefaction within skeletal mus-
cle during the metabolic syndrome including obesity, insu-
lin resistance/type II diabetes mellitus, dyslipidemia, and 
hypertension.28,29 Microvascular dysfunction is a potential 
mechanism in the pathogenesis of obesity-associated insu-
lin resistance and hypertension.30,31 In addition to ANTXR2, 
Table 4. Mean levels of SBP and DBP by rs1458038 genotype and BMI quartile in FAMHES
All participants CC CT TT N β (SE) P
SBP
 Q1 113.3 ± 13.2 112.7 ± 13.6 112.8 ± 13.1 115.1 ± 12.9 499 1.10 (0.82) 0.18
 Q2 116.6 ± 14.4 116.4 ± 15.7 116.6 ± 14.2 117.1 ± 12.2 499 0.37 (0.92) 0.69
 Q3 118.6 ± 14.8 117.7 ± 14.0 118.8 ± 14.8 119.7 ± 16.6 499 1.02 (0.94) 0.28
 Q4 124.3 ± 17.1 122.9 ± 15.8 124.8 ± 16.8 126.0 ± 20.6 499 1.63 (1.12) 0.15
DBP
 Q1 73.5 ± 8.8 73.3 ± 9.3 73.2 ± 8.7 74.3 ± 8.6 499 0.44 (0.55) 0.43
 Q2 75.0 ± 9.3 74.2 ± 9.9 75.6 ± 9.4 75.3 ± 8.2 499 0.68 (0.60) 0.26
 Q3 77.5 ± 9.2 77.0 ± 9.1 77.8 ± 8.8 77.9 ± 10.4 499 0.49 (0.58) 0.40
 Q4 81.6 ± 11.5 80.1 ± 10.3 82.2 ± 11.3 83.0 ± 14.0 499 1.59 (0.75) 0.034
Q1–Q4: the lowest BMI quartile to the highest BMI quartile. Q1: BMI < 20.80; Q2: 20.80 ≤ BMI < 23.04; Q3: 23.04 ≤ BMI < 25.50; Q4: BMI 
≥ 25.50.
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; FAMHES, Fangchenggang Area Male Health and Examination Survey; 
SBP, systolic blood pressure; SE, standard error.
1036 American Journal of Hypertension 28(8) August 2015
Li et al.
FGF5 is also possibly involved in the metabolic syndrome. 
FGF5 encodes fibroblast growth factor 5, a member of the 
fibroblast growth factor (FGF) family. Although FGF5 has 
not yet been shown to have a direct effect on BMI, several 
members of the FGF family have been shown to affect obe-
sity by regulating fatty acid oxidation and lipid metabolism. 
Treatment with exogenous recombinant human FGF21 
protein via infusion or injection can lead to weight loss and 
improvement of lipid profiles in diet-induced obese mice32 
and diabetic rhesus monkeys.33 Transgenic mice express-
ing human FGF19 display increased metabolic rate and 
decreased adiposity.34 The roles of PRDM8 and C4orf22 in 
the pathogenesis of obesity and hypertension are not known.
In conclusion, the association of rs11105378 near ATP2B1 
and rs1458038 near FGF5 with both SBP and DBP were 
replicated in CHNS. In addition, the magnitude of the asso-
ciations between rs1458038, 5′ of FGF5, and blood pres-
sure were modified by BMI in CHNS individuals. While we 
were unable to formally replicate the interaction in a second 
Chinese cohort, evidence from both studies implicate that 
the risk genotype at rs1458038 is particularly important in 
Chinese individuals with higher BMI. To our knowledge, this 
is the first reported interaction between a variant in or near 
FGF5 and BMI on blood pressure. Further studies in Chinese 
and other populations are needed to confirm this finding.
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